Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 826 to 840 of 1257 results for pathway

  1. Robot-assisted surgery for orthopaedic procedures: early value assessment (HTG743)

    Early value assessment (EVA) guidance on robot-assisted surgery for orthopaedic procedures.

  2. Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (TA946)

    Evidence-based recommendations on olaparib (Lynparza) with bevacizumab (Avastin) for high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.

  3. Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

    Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

  4. Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.

  5. Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)

    Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.

  6. Food allergy in under 19s: assessment and diagnosis (CG116)

    This guideline covers assessing and managing food allergy in children and young people under 19. It aims to improve symptoms such as faltering growth and eczema by offering advice on how to identify food allergy and when to refer to secondary or specialist care.

  7. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

  8. Contraceptive services for under 25s (PH51)

    This guideline covers contraceptive services for under-25s. It aims to ensure all under-25s are given advice and information on all types of contraception. This includes additional tailored support to meet the particular needs and choices of those who are socially disadvantaged or who may find it difficult to use these services.

  9. SecurAcath for securing cerebrospinal fluid catheters (MIB107)

    NICE has developed a medtech innovation briefing (MIB) on SecurAcath for securing cerebrospinal fluid catheters .

  10. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

  11. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.

  12. Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)

    Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.

  13. Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment (HTG739)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care.

  14. Urinary tract infection in under 16s: diagnosis and management (NG224)

    This guideline covers diagnosing and managing first or recurrent upper or lower urinary tract infection (UTI) in babies, children and young people under 16. It aims to achieve more consistent clinical practice, based on accurate diagnosis and effective management. It does not cover babies, children and young people with urinary catheters in situ, neurogenic bladders, significant pre-existing urinary tract disorders (uropathies), underlying renal disease or immunosuppression, or recurrent UTI in sexually active girls and young women under 16. It also does not cover babies, children and young people in intensive care units.

  15. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.